Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy

Journal of the American College of Surgeons

Volumn 219, Issue 5, 2014, Pages 1056-1069

  Fang, Sandy H ^a   Efron, Jonathan E ^a   Berho, Mariana E ^b   Wexner, Steven D ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MOLECULAR BIOLOGY; ONCOLOGY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ADJUVANT CHEMOTHERAPY; COLON RESECTION; COLONIC NEOPLASMS; DECISION SUPPORT SYSTEM; PROGNOSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; DECISION SUPPORT TECHNIQUES; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84908270549     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2014.09.010     Document Type: Review

References (93)

1. American Cancer Society: Colorectal Cancer. "What are the key statistics about colorectal cancer?" Available at: www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics. Accessed April 26, 2013.
2. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Colon and Rectum. Available at: http://seer.cancer.gov/statfacts/html/colorect.html. Accessed September 12, 2014.
3. S.B. Edge, D.R. Byrd, C.C. Compton, and A.G. Fritz AJCC Cancer Staging Manual 7th Ed 2010 Springer New York 143 164
4. I.C. Lavery, and L.F. De Campos-Lobato How to evaluate risk and identify stage II patients requiring referral to a medical oncologist: a surgeon's perspective Oncology 2010 2414 2416
5. O.H. Sjo, M.A. Merok, A. Svindland, and A. Nesbakken Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer Dis Colon Rectum 55 2012 307 315
6. G.J. Chang, A.M. Kaiser, and S. Mills Practice parameters for the management of colon cancer Dis Colon Rectum 55 2012 831 843
7. Recommendations for the reporting of resected large intestinal carcinomas. Association of Directors of Anatomic and Surgical Pathology Am J Clin Pathol 106 1996 12 15
8. M.K. Washington, J. Berlin, and P. Branton Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum Arch Pathol Lab Med 133 2009 1539 1551
9. J.T. Wei, E.A. Miller, and J.T. Woosley Quality of colon carcinoma pathology reporting: a process of care study Cancer 100 2004 1262 1267
10. M.R. Griffin, E.J. Bergstralh, and R.J. Coffey Predictors of survival after curative resection of carcinoma of the colon and rectum Cancer 60 1987 2318 2324
11. T. Wiggers, J.W. Arends, and A. Volovics Regression analysis of prognostic factors in colorectal cancer after curative resections Dis Colon Rectum 31 1988 33 41
12. W.K. Blenkinsopp, S. Stewart-Brown, and L. Blesovsky Histopathology reporting in large bowel cancer J Clin Pathol 34 1981 509 513
13. C.C. Compton, L.P. Fielding, and L.J. Burgart Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 2000 979 994
14. P.H. Chapuis, O.F. Dent, and R. Fisher A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer Br J Surg 72 1985 698 702
15. H.E. Mulcahy, M.M. Skelly, A. Husain, and D.P. O'Donoghue Long-term outcome following curative surgery for malignant large bowel obstruction Br J Surg 83 1996 46 50
16. J. Betge, M.J. Pollheimer, and R.A. Lindtner Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting Cancer 118 2012 628 638
17. B.D. Minsky, C. Mies, T.A. Rich, and A. Recht Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer Int J Radiat Oncol Biol Phys 17 1989 311 318
18. C.C. Compton Key issues in reporting common cancer specimens: problems in pathological staging of colon cancer Arch Pathol Lab Med 130 2006 318 324
19. Harris E, Lewin D, Wang H, et al. Lymphovascular invasion in colorectal cancer an interobserver variability study Am J Surg Pathol 2008;32:1816-1821.
20. T. Arigami, S. Natsugoe, and Y. Uenoso Lymphatic invasion D2-40 monoclonal antibody and its relationship to lymph node metastasis Br J Cancer 93 2005 688 693
21. E.F. Kingston, H. Goulding, and A.C. Bateman Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining Dis Colon Rectum 50 2007 1867 1872
22. G. Ceyhan, F. Liebl, and M. Maak The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy Ann Surg 252 2010 797 804
23. C. Liebig, G. Ayala, and J. Wilks Perineural invasion is an independent predictor of outcome in colorectal cancer J Clin Oncol 27 2009 5131 5137
24. M. White, A.K. Foulis, and G. Smith The role of S100 staining in the pathological assessment of perineural invasion in rectal cancer Colorectal Dis 16 2013 71 72
25. T.B. Halvorsen, and E. Seim Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer J Clin Pathol 42 1989 162 166
26. N.A. Shepherd, E.P. Saraga, S.B. Love, and J.R. Jass Prognostic factors in colonic cancer Histopathology 14 1989 613 620
27. K. Hase, C. Shatney, and D. Johnson Prognostic value of tumor "budding" in patients with colorectal cancer Dis Colon Rectum 36 1993 627 635
28. S. Popat, R. Hubner, and R.S. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609 618
29. G.P. Kim, L.H. Colangelo, and H.S. Wieand Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J Clin Oncol 25 2007 767 772
30. M. Donada, S. Bonin, and R. Barbazza Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision BMC Gastroenterol 13 2013 36
31. S. Kopetz, and J.L. Abbruzzese Barriers to integrating gene profiling for stage II colon cancer Clin Cancer Res 15 2009 7451 7452
32. C.M. Ribic, D.J. Sargent, and M.J. Moore Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247 257
33. S. Ogino, K. Shima, and J.A. Meyerhardt Predictive and prognostic roles of BRAF mutation in stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 Clin Cancer Res 18 2012 890 900
34. N.S. Goldstein Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities Am J Surg Pathol 26 2002 179 189
35. P.F. Engstrom, J.P. Arnoletti, and A.B. Benson III NCCN Clinical Practice Guidelines in Oncology: colon cancer J Natl Compr Canc Netw 7 2009 778 831
36. L. Sarli, G. Bader, and D. Iusco Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer Eur J Cancer 41 2005 272 279
37. R.S. Swanson, C.C. Compton, A.K. Stewart, and K.I. Bland The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined Ann Surg Oncol 10 2003 65 71
38. T.E. Le Voyer, E.R. Sigurdson, and A.L. Hanlon Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089 J Clin Oncol 21 2003 2912 2919
39. G.J. Chang, M.A. Rodriguez- Bigas, and J.M. Skibber Lymph node evaluation and survival after curative resection for colon cancer: systematic review J Natl Cancer Inst 99 2007 433 441
40. C. Budde, V. Tsikitis, and K. Deveney Increasing the number of lymph nodes examined after colectomy does not improve colon cancer staging J Am Coll Surg 218 2014 1004 1011
41. J. Wong, R. Severino, and M.B. Honnebier Number of nodes examined and staging accuracy in colorectal carcinoma J Clin Oncol 17 1999 2896 2900
42. J. Namm, M. Ng, and S. Roy-Chowdhury Quantitating the impact of stage migration on staging accuracy in colorectal cancer J Am Coll Surg 207 2008 882 887
43. H. Parsons, T. Tuttle, and K. Kuntz Association between lymph node evaluation for colon cancer and node positivity over the past 20 years JAMA 306 2011 1089 1097
44. N. Baxter, R. Ricciardi, and M. Simunovic An evaluation of the relationship between lymph node number and staging an pT3 colon cancer using population-based data Dis Colon Rectum 53 2010 65 70
45. G.J. Chang, M.A. Rodriguez-Bigas, J.M. Skibber, and V.A. Moyer Lymph node evaluation and survival after curative resection of colon cancer: systematic review J Natl Cancer Inst 99 2007 433 441
46. S.S. Shen, B.X. Haupt, and J.Y. Ro Number of lymph nodes examined and associated clinicopathological factors in colorectal carcinoma Arch Pathol Lab Med 133 2009 781 786
47. S.L. Chen, and A.J. Bilchik More extensive nodal dissection improves survival for stages I to III of colon cancer: A population-based study Ann Surg 244 2006 602 610
48. K. Soreide, E.A. Janssen, and H. Soiland Microsatellite instability in colorectal cancer Br J Surg 93 2006 395 406
49. P.M. Johnson, D. Malatjalian, and G.A. Porter Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study J Gastrointest Surg 6 2002 883 888
50. W. Sanchez, P. Luna-Perez, and I. Alvarado Modified clearing technique to identify lymph node metastasis in post-irradiated surgical specimens from rectal adenocarcinoma Arch Med Res 1 1997 31 36
51. H. Wang, B. Safar, and S.D. Wexner The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy Dis Colon Rectum 52 2009 1767 1773
52. S. Gill, C.L. Loprinzi, and D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 2004 1797 1806
53. V.S. Tammana, and A.O. Laiyemo Colorectal cancer disparities: issues, controversies, and solutions World J Gastroenterol 20 2014 869 876
54. D. Alexander, C. Chatla, and E. Funkhouser Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma Cancer 101 2004 66 76
55. A.B. Benson III, J.A. Ajani, and R.B. Catalano Recommended guidelines for the treatment of cancer treatment-induced diarrhea J Clin Oncol 22 2004 2918 2926
56. F. Di Costanzo, A. Sobrero, and S. Gasperoni Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) Ann Oncol 14 2003 1365 1372
57. D.G. Haller, P.J. Catalano, and J.S. Macdonald Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089 J Clin Oncol 23 2005 8671 8678
58. C.C. Lin, J.K. Lin, and S.C. Chang Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute Int J Colorectal Dis 24 2009 665 676
59. T. Andre, C. Boni, and M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
60. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204
61. A.B. Benson, D. Schrag, and M.R. Somerfield ASCO recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 2004 3408 3419
62. R. Gray, J. Barnwell, and C. McConkey Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 370 2007 2020 2029
63. X. Wu, J. Zhang, and X. He Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials J Gastrointest Surg 16 2012 646 655
64. N.O. Vietor, and B.J. George Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent J Oncol Pharm Pract 18 2012 355 359
65. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease Prescrire Int 20 2011 46 49
66. D.J. Sargent, R.M. Goldberg, and S.D. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 2001 1091 1097
67. M.L. Rothenberg, N.J. Meropol, and E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
68. D. Schrag, S. Rifas-Shiman, and L. Saltz Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer J Clin Oncol 20 2002 3999 4005
69. Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 3 2014 www.nccn.org/professionals/phiciangls/pdf/colon.pdf. Accessed September 12, 2014.
70. D. Otchy, N. Hyman, and C. Simmang Practice parameters for colon cancer Dis Colon Rectum 47 2004 1269 1284
71. R. Labianca, B. Nordlinger, and D. Beretta Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up Ann Oncol 24 2013 vi64 vi72
72. T. Watanabe, M. Itabashi, and Y. Shimada Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer Int J Clin Oncol 17 2012 1 29
73. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee Guidelines for the Prevention Early Detection and Management of Colorectal Cancer 2005 The Cancer Council Australia and Australian Cancer Network Sydney
74. A. Figueredo, M.E. Coombes, and S. Mukherjee Adjuvant therapy for completely resected stage II colon cancer Cochrane Database Syst Rev 16 2008 CD005390
75. H.M. Kirkpatrick, C.L. Aitelli, and H. Qin Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer Clin Colorectal Cancer 9 2010 150 156
76. J.S. Haas, P. Brawarsky, and A. Iyer Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality Cancer 117 2011 4267 4276
77. G. Yothers, D.J. Sargent, and N. Wolmark Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials Natl Cancer Inst 103 2011 1498 1506
78. P.A. Newcomb, and P.P. Carbone Cancer treatment and age: patient perspectives J Natl Cancer Inst 85 1993 1580 1584
79. R.U. Osarogiagbon, J.C. Sachdev, A.G. Khattak, and L.E. Kronish Pattern of use of adjuvant chemotherapy for stage II colon cancer: a single-institution experience Clin Colorectal Cancer 8 2009 94 99
80. R.K. Kelley, and A.P. Venook Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer 10 2011 73 80
81. K.M. Clark-Langone, C. Sangli, J. Krishnakumar, and D. Watson Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay BMC Cancer 10 2010 691
82. G. Yothers, M.J. O'Connell, and M. Lee Validation of the 12 gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin J Clin Oncol 31 2013 4512 4519
83. G. Srivastava, L.A. Renfro, and R.J. Behrens Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage ii colon cancer patients Oncologist 2014 [Epub ahead of print]
84. R. Salazar, P. Roepman, and G. Capella Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer J Clin Oncol 29 2011 17 24
85. M. Maak, I. Simon, and U. Nitsche Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer Ann Surg 257 2013 1053 1058
86. R.D. Kennedy, M. Bylesjo, and P. Kerr Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue J Clin Oncol 29 2011 4620 4626
87. J.B. O'Connell, M.A. Maggard, and C.Y. Ko Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging J Natl Cancer Inst 96 2004 1420 1425
88. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer J Clin Oncol 13 1995 2936 2943
89. S. De Dosso, C. Sessa, and P. Saletti Adjuvant therapy for colon cancer: present and perspectives Cancer Treat Rev 35 2009 160 166
90. A. Figueredo, M.L. Charette, and J. Maroun Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group J Clin Oncol 22 2004 3395 3407
91. P. Quirke, G.T. Williams, and N. Ectors The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol 8 2007 651 657
92. P. Quirke, C. Cuvelier, and A. Ensari Evidence-based medicine: the time has come to set standards for staging J Pathol 221 2010 357 360
93. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer Lancet 345 1995 939 944